Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma

(MedPage Today) -- Treatment with single-agent pirtobrutinib (Jaypirca), a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news